Article
Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
Clinical lung cancer - 1 May 2024
Ou Sai-Hong Ignatius, Prawitz Thibaud, Lin Huamao M, Hong Jin-Liern, Tan Min, Proskorovsky Irina, Hernandez Luis, Jin Shu, Zhang Pingkuan, Lin Jianchang, Patel Jyoti, Nguyen Danny, Neal Joel W
Abstract excerpt
INTRODUCTION: Exon 20 insertions (ex20ins) mutations of the EGFR gene account for 1% to 2% of all non-small-cell lung cancers (NSCLCs). Targeted therapies have been developed to treat this cancer type but have not been studied in head-to-head trials. Our objective was to use a matching-adjusted indirect comparison (MAIC) to assess the efficacy of mobocertinib and amivantamab in patients with NSCLC EGFR ex20ins...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.